Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study

ConclusionsAs a first-in-class antifungal agent, ibrexafungerp demonstrated promising efficacy and favorable safety for VVC treatment in Chinese patients.Chinadrugtrials.org.cn registry numberCTR20220918.

http://link.springer.com/10.1007/s15010-024-02233-w

Source: Infection - April 3, 2024 Category: Infectious Diseases Source Type: research